NCT00787150 - A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation | Biotech Hunter

Enrollment

222

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Atrial Fibrillation

Interventions

DRUG

Apixaban

Apixaban 5 mg tablet BID for 12 weeks

DRUG

Apixaban

Apixaban 2.5 mg tablet BID for 12 weeks

DRUG

Warfarin sodium

At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks

Trial Locations (18)

Pfizer Investigational Site, Nagoya

Pfizer Investigational Site, Seto

Pfizer Investigational Site, Touon

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Kitakyushu

Pfizer Investigational Site, Ōgaki

Pfizer Investigational Site, Isesaki

Pfizer Investigational Site, Shibukawa

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Higashiibaraki-gunn Ibarakimachi

Pfizer Investigational Site, Zentsujichó

Pfizer Investigational Site, Kawasaki

Pfizer Investigational Site, Kumamoto

Pfizer Investigational Site, Tsu

Pfizer Investigational Site, Minato-ku

Pfizer Investigational Site, Shinagawa-ku

Pfizer Investigational Site, Shinjuku-ku

Pfizer Investigational Site, Iwakuni